---
document_datetime: 2025-09-03 11:25:29
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/casgevy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: casgevy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9899016
conversion_datetime: 2025-12-30 11:59:39.667694
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Casgevy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 24/07/2025                          |                                             | SmPC and PL                      | SmPC new text The following warning has been |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000258214   | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 5.3 of the SmPC in order to update information on off-target editing based on (1) Results of in silico analysis to nominate genetic variants and (2) Interim study report presenting results from genotyping of subjects and off-target editing in drug product from subjects in clinical Studies 111 and 121. In addition, the MAH took the opportunity to make editorial to the PI.   | changes   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     | expressed in haematopoietic cells. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000258235 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently | 25/04/2025 | N/A |                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                            | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted   |                                                                                                                                                                                                                                                                   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248449 | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing exagamglogene autotemcel remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |